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ARTICLE

A Physiologically-Based Pharmacokinetic Model for
Targeting Calcitriol-Conjugated Quantum Dots to
Inflammatory Breast Cancer Cells
James Forder1, Mallory Smith1, Margot Wagner1, Rachel J. Schaefer2, Jonathon Gorky3, Kenneth L. van Golen2, Anja Nohe2 and
Prasad Dhurjati1,*

Quantum dots (QDs) conjugated with 1,25 dihydroxyvitamin D3 (calcitriol) and Mucin-1 (MUC-1) antibodies (SM3) have been
found to target inflammatory breast cancer (IBC) tumors and reduce proliferation, migration, and differentiation of these
tumors in mice. A physiologically-based pharmacokinetic model has been constructed and optimized to match experimental
data for multiple QDs: control QDs, QDs conjugated with calcitriol, and QDs conjugated with both calcitriol and SM3 MUC1
antibodies. The model predicts continuous QD concentration for key tissues in mice distinguished by IBC stage (healthy,
early-stage, and late-stage). Experimental and clinical efforts in QD treatment of IBC can be augmented by in silico simulations that predict the short-term and long-term behavior of QD treatment regimens.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Recent studies have indicated that calcitriol has
beneficial effects against SUM149 inflammatory breast
cancer (IBC) proliferation, migration, and differentiation.
Although preliminary studies on calcitriol-conjugated
quantum dots (QDs) injected into mice with IBC have
been encouraging, no model exists to predict the distribution of these QDs.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ The study addresses the parameters, connectivity,
and mathematical relationships needed to construct a
model to predict dynamic QD distribution in mice with
IBC.

Inflammatory breast cancer (IBC) is an aggressive form of
cancer, which makes up ~ 1–5% of breast cancer cases
but accounts for 10% of breast cancer deaths annually in
the United States.1 Often, this form of cancer is difficult to
diagnose and is typically not recognized until it has progressed to stage III or IV.1 The median survival time after
diagnosis is <15 months with recurrence rates as high as
50%.2 Traditional treatment plans consisting of surgery
and localized radiotherapy result in a <5% survival rate beyond 5 years, the lowest survival rate of any breast cancer subtype.2 With more advanced treatment combining
multiple-targeting approaches, IBC still only has 5-year
and 10-year disease-free survival rates of <45% and 20%,
respectively.2
1

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ A physiologically-based pharmacokinetic model framework has been constructed and validated for multiple QDs,
notably SM3 calcitriol QDs. Continuous QD concentration
estimates for key tissues can be generated, with the ability for
adjustments to cover a broad range of patient characteristics.
HOW MIGHT THIS CHANGE CLINICAL PHARMA
COLOGY OR TRANSLATIONAL SCIENCE?
✔ The PBPK model provides a framework to guide or complement both experimental and clinical endeavors in QD
treatment of IBC and to infer behavior of experiments not
performed. With additional data, the model has the potential
to provide further mechanistic understanding of the disease.

IBC is a rapidly progressing and highly metastatic disease with a younger age of onset relative to other types of
breast cancer.2 Typical symptoms include erythema, edema,
and thickening or pitting of the breast, which is caused by
tumor emboli blocking dermal lymph drainage.3 By the time
discernable symptoms are present, IBC is already locally
advanced as the breast cancer cells have grown into surrounding structures and sometimes to distant metastasis
sites, commonly in the bone, lungs, and skin.4,5 These nonspecific symptoms, especially in absence of the stereotypical lump formation, are often misidentified as an infection
or rash leading to IBC being misdiagnosed as mastitis or
generalized dermatitis, delaying the treatment of the underlying cancer.1,2 As a result, when diagnosed with IBC, almost
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all women are lymph node–positive with approximately onethird having distant metastases.2
Current treatment involves a multiple-targeting approach
due to the aggressive nature of IBC. Hormone treatment
is ineffective for many patients with IBC because approximately one-third of IBC diagnoses are triple-negative.1,2
Instead, current treatment plans involve systemic chemotherapy followed by a mastectomy to remove the tumor and
surrounding tissue and finally localized radiotherapy.1,2 In
addition to this, patients with IBC are often prescribed vitamin D supplements due to the vitamin’s beneficial effect
on reducing the cancer’s metastasis rate.6 Despite this multimodality treatment plan, prognosis for patients with IBC
is poor. Researchers are pursuing an improved treatment
method for IBC, ideally one that could prevent tumor cell
migration as well as preventing or disrupting the formation
of tumor emboli.2
A potential new therapeutic is the active form of vitamin
D, 1,25 dihydroxyvitamin D3 (calcitriol). Calcitriol is known to
modulate calcium and phosphate homeostasis to maintain
bone health; it is most biologically active in tissues positive
for vitamin D receptors, including organs, such as the kidney
and intestines, as well as bone and the parathyroid gland.7,8
Recently, vitamin D has been demonstrated to be a regulator
of breast cancer cell proliferation, invasion, migration, differentiation, and apoptosis in vitro. The antiproliferative effects
are thought to be a result of calcitriol blocking the mitogenic
effects of insulin-like growth factor I through downregulation
of its receptors, causing the G1 phase of the cell cycle to
pause.9 In addition, it was found that SUM149 cells exposed
to calcitriol exhibited a decreased ability to migrate, invade,
and form tumor emboli, leading to decreased metastasis in
vivo.10,11 However, previous studies have required toxic dosages of calcitriol (over 0.50 μg) to have a significant effect,
which would lead to hypercalcemia.10–12 Therefore, targeting
methods are required to reach desired levels of calcitriol at
treatment sites without having an excess of calcitriol in the
rest of the body.
Quantum dots (QDs) conjugated to calcitriol have previously been used to examine the distribution of calcitriol both
in vitro and in vivo.10,11 QDs are semiconductor nanoparticles
around 15 nm in diameter, which can be used for fluorescent
imaging under UV light and have a variety of surface chemistries that are compatible with living systems. They localize
in the liver, lymph nodes, kidneys, and spleen in mice, with
some effects on distribution from the polymer surface chemistry (conjugated with carboxyl groups in this case).10 To use
calcitriol QDs for direct imaging of live cells, QDs are conjugated to calcitriol using an esterification reaction to produce
calcitriol QDs (CalQDs).10,11 To avoid hypercalcemia and potential toxicity, these CalQDs can be manipulated to target
tumor sites. Unlike other forms of breast cancer, IBC cells
overexpress a hypoglycosylated form of Mucin-1 (MUC1), a
glycoprotein that is expressed on the apical surface of epithelial cells. Recently, Schaefer et al.10,11 have proposed a
therapeutic method conjugating SM3 MUC1 antibodies with
CalQDs (SM3 CalQDs). In their studies, Schaefer et al.10,11
used florescent imaging to measure the accumulation of
SM3 CalQDs in various organs as well as tumor tissue in
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mice with SUM149 IBC tumors. The SM3 CalQDs were
shown to target MUC1 overexpressing IBC cells, identify
localization of IBC tumor emboli, and act as a vehicle to administer calcitriol more directly to affected areas, mitigating
hypercalcemia and other negative side effects.
To better elucidate the details of the distribution of SM3
CalQDs as well as finding an adequate dosing regimen, we
look to create a physiologically-based pharmacokinetic
(PBPK) model. However, one of the challenges in creating
a model that demonstrates the distribution of SM3 CalQDs
is capturing physiological differences due to the extent of
tumor growth. In the early stages of IBC, the cancer cells are
localized within the breast tissue. During the course of the
disease, 70% of patients with IBC develop a distant metastasis, suggesting the need to model different dynamics for
early-stage compared to late-stage IBC.2 Additionally, acute
inflammatory response to cancer can cause the spleen to
become enlarged.13 To demonstrate the dynamics of SM3
CalQDs in both early and late-stage cancer as well as a
healthy mouse, three distinct models will be created characteristic of each stage.
METHODS
PBPK model
This PBPK model for the distribution of CalQDs in mice for
use in IBC treatment is based on a priori physical laws and
parameters. The organs included are those most relevant
to CalQD distribution during the particular cancer phase
being modeled. In both early-stage and late-stage cancer
models, the plasma compartment behaves as the central
compartment by which the QDs are carried to and from
the other tissues. The treatment is modeled as an intravenous injection, so the substance is directly inserted into the
plasma compartment as system input. The lungs, spleen,
liver, and kidneys are included as they are richly perfused
organs and have been shown to preferentially accumulate
the QDs tested by Schaefer et al.8,10,12 As IBC generates
a large immune response, the spleen compartment is also
used to model the influence of splenomegaly often seen
in patients with cancer. The liver receives blood flow from
the spleen and is vital for clearance and breakdown of the
CalQDs in the body via biliary secretion.14,15 Additionally,
the lungs are one of the most common sites for early IBC
metastasis. Previous studies have shown that QDs injected intravenously in mice localize in the liver, kidneys,
and spleen.10,14 The “other” compartment was included as
a lumped compartment for tissues not explicitly mentioned.
In late-stage models, a tumor compartment is included
in parallel to the other organs to represent delocalized
tumor tissue throughout the body due to metastasized
tumors. In contrast, in the early-stage model, a tumor is
housed in a compartment parallel to the breast so that it
is surrounded by breast tissue. These organs were connected according to their vascular connections in the
human body (Figure 1).
Assumptions
The concentration of CalQDs in each compartment in the
model was based on the dynamics of a continuous-stirred
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Figure 1 Physiologically-based pharmacokinetic connectivity for healthy, nontumor case (left), early-stage tumor (middle), and latestage tumor (right).

tank reactor that is well mixed and perfusion limited. The
well-mixed assumption states that each organ or tissue region is homogeneous, with immediate mixing such that the
inlet flow concentration instantaneously equilibrates with
the concentration in the tank and efflux. The ubiquity of capillaries in the body and the well-defined uniform exchange
of QDs across these capillaries validate this assumption.
Furthermore, the interstitial spaces of most organs tend to
be uniform such that the concentration of substances entering/exiting the bloodstream is the same across the organ.
Because the blood stream contains uniformly mixed QDs,
the organs do as well, each according to their diffusion and
perfusion properties. The perfusion-limited (or flow-limited)
assumption states that diffusion is limited by regional blood
flow into the capillaries of an organ or tissue. A corollary
from this is that tissue membranes offer no significant resistance to molecular flow relative to the blood flow; diffusion across any membrane is very fast compared with
blood transport. The perfusion-limited assumption is akin
to the quasi-steady-state approximation used in chemical
engineering kinetics. This is a valid assumption based on
the small size of CalQDs and minimal interactions with the
tissue membranes.11
Parameter selection
The main parameters of interest to construct this PBPK
model are the physiological parameters of our organism of
interest, the biophysical behavior of our substance of interest, and the interactions between the two in the form of
partition coefficients. Fixed parameters of this model are
compartment volumes and volumetric flowrates, whereas

partition coefficients were varied among the healthy, early-stage, and late-stage models.
Organ masses can be found in literature for a multitude of
organs and organisms as a fraction of body weight (BW).16,17
Schaefer et al.10 used female mice between the ages of
13–16 weeks, which have a mass of ~ 22.0 g.16,17 Knowing
the BW of the mouse, organ masses can be determined
using the mean percent BW of each organ. From organ
masses, organ volumes can be determined via the specific
gravity of each organ. For the majority of organs or tissue
regions, a specific gravity of 1.0 can be assumed as they are
generally in this range (1.02–1.06) because they are composed primarily of water.15,18 There are a few notable exceptions: marrow-free bone has a density of 1.92 g/cm3, and
the density of adipose tissue in mice is 0.916 cm3/100 g BW.
To determine the mass of adipose in a mouse, the following
equation can be used19:

(%BW) = 0.0199(BW) + 1.664

(1)

Excluding the adipose and bone, the rest of the “other”
compartment volume was determined using a specific
gravity of 1.0. These three were then added for the lumped
“other” compartment. Compartmental volumes for the
model are shown in Table 1.
For a 22.0-g mouse with late-stage IBC, we used the
tumor measurement given by Schaefer et al.10 This value
was also used to approximate the early-stage tumor—a
small error considering the small size of the tumor—
whereas the breast tissue BW was based on the weight
of mammary glands reported by Fisher et al.20 In the
early-stage model, the breast compartment was created
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Table 1 Compartmental volume and blood plasma volumetric flow
rate parameters

Compartment

Volume (mL)

Volumetric flow rate
(mL/hour)
944.3

Blood plasma

1.078

Lungs

0.1606

4.713

Kidneys

0.3674

85.77

Spleen

0.077 (0.154)

18.85

Liver

1.208

132.9

Breast

1.05

22.79

Tumor

0.08

1.766

Other

55.76

677.5

kelim = 1.0 × 10−6 hr−1

Compartmental volumes and volumetric flowrates were calculated from
literature for a 22-g mouse.14,15 The volume of the enlarged spleen case is
shown in parenthesis. The tumor compartment volume and blood plasma
flow rate were kept the same between the early-stage and late-stage models, so the values are an overestimate for the early-stage model.

by subtracting the volume for the breast tissue from the
“other” organ compartment while maintaining a constant
volume for the other organs.
The blood flow rate to each tissue region is given as a
fraction of total cardiac output. The total cardiac output for
our 22.0 g female mouse can be estimated from the following equation where BW is given in kilograms19:

Cardiac output (L∕min) = 0.275(BW)0.75

The sink for QDs is from the liver compartment as biliary excretion, which takes the form of a first-order kinetic
degradation of concentration with time. The following estimation for the first-order clearance rate constant was previously validated from experimental data for QD 705.14 The
value is very small because QD clearance from the body
is slow with significant concentrations still measured even
28 days after intravenous injection.

(2)

From the mean percent cardiac outputs, blood flow to
each organ can be determined. Additionally, the flow rate
to the tumor is based on previously measured tumor blood
flow rate scaled to our tumor size.21 Compartmental volumetric flow rates are shown in Table 1.
QDs are injected intravenously into the organism, so the
input to the model is a pulse into the plasma compartment.
Effectively, this behaves as the plasma compartment starting with an initial concentration based on the dosage and
distributing to the rest of the body as time progresses.

(3)

A partition coefficient is the equilibrium tissue-to-blood
partition coefficient, a proportionality constant relating the
tissue concentration of a substance X to the outgoing venous
concentration. In the perfusion-limited case, it describes the
ratio of the total tissue concentration of a substance X to its
concentration in the outgoing blood flow. In practice, partition
coefficients are approximated by the empirical equilibrium
partition coefficient, which effectively lumps all processes
that alter tissue extraction together in one term and is estimated experimentally using in vitro experimentation.18 Due
to the novelty of the QDs in this model, experimental partition
coefficients do not yet exist, so estimation will be used going
forward based on measured QD intensities (Table 2).10,11
Some partition coefficients are available for a similar QD
(Table S1)14; assuming that conjugating calcitriol to QDs does
not significantly affect the distribution of QDs in tissue we can
use these values as a starting point. The initial partition coefficient estimates for the tumor compartment were based on the
QD in question, with a low value used for the untargeted QDs
and a much higher value used for targeted QDs, to consider the
preferential attraction of SM3 CalQDs to IBC tumor cells that
is expected due to the conjugated SM3 MUC1 antibodies.10
System of equations
The equations for the compartments are mass flow balances across homogeneous, well-stirred tissues with influx
and efflux. Blood flows at the same volumetric flow rate, Q,

Table 2 Mean pixel intensity of QDs in organs of mice with no tumor and with late-stage tumor
No tumor

Late-stage tumor

QD

Organ

Intensity

Error (%)

Intensity

ConQD

Kidney

10.40

10.22

12.54

17.52

Liver

16.23

22.20

14.85

16.91

Lung

4.66

16.21

8.22

2.24

Spleen

12.73

9.08

26.43

11.21

CalQD

SM3 CalQD

Error (%)

Kidney

11.01

9.14

15.15

20.58

Liver

20.38

12.99

20.15

31.96

Lung

3.16

8.07

7.59

5.27

Spleen

10.99

10.45

21.46

20.06

Kidney

10.47

12.67

11.57

17.98

Liver

17.18

6.91

18.12

8.22

Lung

5.01

16.57

7.46

12.94

Spleen

9.87

11.70

17.92

8.14

CalQD, calcitriol quantum dot; ConQD, control (unconjugated) QD; SM3, Mucin-3 antibodies; QDs, quantum dots.
Mice with and without SUM149 inflammatory breast cancer tumors were injected with SM3 CalQDs, CalQDs, or ConQDs, and after 4 days florescent images
were taken. The mean pixel intensity values were reproduced with this model by fitting partition coefficient values with a residual sum of squares minimization.10 The intensities reported for the late-stage tumor were also used for the early-stage model.
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into and out of each constant compartment volume, V. The
change in concentration with respect to time, Ċ , is equivalent to the blood flow rate divided by the constant volume,
all multiplied by the concentration gradient across the compartment. The gradient can be represented by the change in
concentration of a substance in the inflow (arterial concentration) compared with the outflow (venous concentration)
due to distribution into the tissue. Additionally, an organ may
have a sink or source, which will be represented here as a
rate, R. Overall, this gives Eq. 4 for a single organ system.

Q
Ċ = (ci − co ) + R
V

c
co

(5)

Substituting this into Eq. 4, we have the following equation to describe a single organ system:

c
Q
Ċ = (ci − ) + R
V
P

(8)

Qtotal = Qkidney + Qliver + Qspleen + Qlung + Qother

Ċ lung(l) =

(

Ċ spleen(s) =

Ċ liver(li) =

(

1
Vli

)[

(

Ql
Vl

(

)[

Qk
Vk

)[

Qs
Vs

Qli Cp + Qs

Ċ other(o) =

(

Qo
Vo

Cp −

Cb −

)[

Cl
Pl

Cp −

]

Ck
Pk

Cp −

(9)

]

Cs
Ps

(10)

]

C
Cs
− (Qli + Qs ) li − kCli
Ps
Pli

)[

Ċ tumor(t) =

Co
Po

]

(11)

]

(12)
(13)

For the late-stage IBC case, the blood plasma compartmental balance and overall molar flow equations change, as

(

)[

Qt
Vt

Cp −

Ct
P

]

(16)

In the case with an early-stage tumor, the equations remain the same except for those pertaining to the tumor and
blood. In addition, a breast compartment is added, making
these equations as follows:
)
( ) {[(
) Cli
(
Qk Ck
1
+ Qli + Qs
Ċ plasma (p) =
(17)
Vb
Pk
Pli
(
) (
) (
)]
}
Ql Cl
Qo Co
Qbr Cbr
+
+
+
− (Qtotal )Cb
Pl
Po
Pbr

Qtotal = Qkidney + Qliver + Qspleen + Qlung + Qother + Qbreast (18)

(6)

Thus, for our healthy, nontumor system, containing the
kidneys, liver, lungs, spleen, and plasma, with pulse input
and excretion from the liver following first-order kinetics,
we have the following set of differential equations with conserved volumetric flowrate:
)
( ) {[(
) Cli
(
Qk Ck
1
̇C
+ Qli + Qs
plasma(p) =
Vp
Pk
Pli
(7)
(
) (
)]
}
Ql Cl
Qo Co
+
+
− (Qtotal )Cp
Pl
Po

Ċ kidney(k) =

Qtotal = Qkidney + Qliver + Qspleen + Qlung + Qother + Qtumor (15)

(4)

Because we are interested in the concentration in the actual
tissue rather than in the circulatory system, we will utilize the
partition coefficient, P, the ratio of concentration of substance
X in the tissue, c, to the incoming plasma concentration of substance X, co. For compartments connected to the plasma compartment, co is the venous concentration of the substance.

P=

well as the addition of a tumor equation. All other equations
remain the same.
)
( ) {[(
) Cli
(
Qk Ck
1
+ Qli + Qs
Ċ plasma(p) =
(14)
Vp
Pk
Pli
(
) (
) (
)]
}
Ql Cl
Qo Co
Qt Ct
+
+
+
− (Qtotal )Cp
Pl
Po
Pt

Ċ breast (br) =

(

1
Vbr

)[

Cp Qbr +

Ċ tumor(t) =

(

Qt
Vt

C Q
Ct Qt
− Cbr Qt − br br
Pt
Pbr

)[

Cbr −

Ct
Pt

]

]

(19)

(20)

Equations were solved simultaneously using the built-in
function ode23s on MATLAB R2017b. All above parameters were constants found in literature except for the partition coefficients, which were varied from their original
estimations such that model results match experimental
florescence data 4 days after dosage in Table 2 via a residual sum of squares minimization. As there are no fluorescence data available for mice with early-stage IBC, the
data for the late-stage model are used. This results in significant error as the difference between the early-stage and
late-stage models is only the change in connectivity. In the
unhealthy, tumor cases, the model estimates the concentration of QDs in tumor tissue as well. In addition, the effect
of doubling the volume of the spleen on the organ partition
coefficients and model results was analyzed. Although we
will look at an increased spleen volume, we maintain the
spleen blood flow rates.
RESULTS
Partition coefficients
There is a lack of experimental information available on
the QDs in question as the proposed treatment is a recent
and novel development. The QDs have been found to accumulate in specific tissues,8,10,12 so the partition coefficient for the “other” compartment was assumed to be 1.
For all additional compartments, the partition coefficients
www.cts-journal.com
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Table 3 Compartmental partition coefficient values for the three models
No tumor

Early-stage tumor

Late-stage tumor

ConQD

CalQD

SM3 CalQD

ConQD

CalQD

SM3 CalQD

ConQD

CalQD

SM3 CalQD

Kidney

32.7

46.9

34.8

45.1

91.2

59.1

41.7

74.1

46.6

Liver

50.9

86.3

56.8

53.4

121.2

92.6

49.3

98.3

72.8

Spleen

40.0

46.9

32.8

95.0

129.1

91.5

88.0

105.0

72.3

Lung

14.6

13.4

16.6

29.6

45.7

38.1

27.3

37.1

30.1

Tumor

—

—

—

28.6

45.5

97.4

24.9

23.8

98.1

Breast

—

—

—

2.67

1.71

1.83

—

—

—

Compartment

CalQD, calcitriol quantum dot; ConQD, control (unconjugated) QD; SM3, Mucin-3 antibodies.
Partition coefficients were found through a residual sum of squares minimization with experimental QD concentration data. The partition coefficient for the
other compartment for each model was assumed to be 1.

used for each model are shown in Table 3, with the values for the enlarged spleen case shown in Table S2. In
each case, tumor partition coefficients are much higher
for the SM3 CalQDs compared with the untargeted QDs.
However, tumor compartment partition coefficients are
significantly sensitive to the initial estimate used as the
compartmental volume is very small and the experimental concentration in the cancer cells for each is unknown.
Additionally, partition coefficients for the kidney, liver,
spleen, and lung compartments all increase under the enlarged spleen case. For SM3 CalQDs, this led to a lower
concentration in the tumor compartment, especially for
the early-stage case.
Model results
Normalized time-concentration graphs for SM3 CalQDs
for each model (no tumor, early-stage tumor, and latestage tumor) are shown in Figure 2. The maximum concentration of SM3 CalQDs in the tumor compartment is
~ 20% higher for the late-stage model than the early-stage.
Additional plots for untargeted CalQDs and unconjugated
control QDs (ConQDs) are in Figures S1 and S2. Figure
S3 is a reproduction of Figure 2 extended to 4 days. These

results show a very fast convergence to a steady concentration in each compartment except the tumor, which has
a slower increase due to the relatively small blood plasma
flow rate to the compartment. In the early-stage case, the
breast compartment QD concentration remains low in
comparison with the tumor compartment due to the large
disparity in their partition coefficients and relatively small
size of the tumor compartment. QD concentrations in the
spleen and kidneys quickly peak before decreasing and
redistributing some of the QDs to other compartments.
Other tissue regions exhibit a monotonic increase over the
entire time span.
In Figure 3, QD concentration profiles in the spleen compartment for the normal and enlarged spleen cases are compared in the late-stage model. The enlarged spleen volume
is used as an example of a potential application of the model
to describe changes in QD distribution due to a common
symptom of cancer. Of note is the loss of an initial peak before reaching a relatively steady-state value; this behavior
represents a relative loss in blood flow to the spleen. These
dynamics are mirrored in the early-stage case. Other compartmental time-concentration profiles are qualitatively unaffected by spleen volume.

Figure 2. SM3 calcitriol quantum dot healthy (left), early-stage (middle), and late-stage (right) time-concentration results for regular
spleen size. Concentration values are normalized by the initial concentration in the plasma compartment. The results are shown only
to 4 or 12 hours, as concentrations afterward are steady state and scaling the figure would obscure these dynamics. SM3, Mucin-3
antibodies.
Clinical and Translational Science
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Figure 3 Late-stage spleen compartment concentration for
SM3 calcitriol quantum dots (CalQDs; red), CalQDs (purple),
and ConQDs (blue) with corresponding enlarged spleen
results (dotted). Results for the early-stage model are similar.
Concentration values are normalized by the initial concentration
in the plasma compartment. ConQD, control (unconjugated) QD;
SM3, Mucin-3 antibodies.

DISCUSSION
Overall, it was shown that a PBPK model can be used
to describe the behavior and distribution of QDs both in
healthy and tumorous mice. Although partition coefficient
data for any of the QDs in question are unavailable, estimated partition coefficients were found that produced
simulated data consistent with that found experimentally.
This model generates continuous time-concentration
data of QDs in several tissue regions, which can be useful
for quantifying short-term and long-term behavior of the
various QDs in each tissue region.
In all simulations, no QD concentration exceeds the initial dosage, so hypercalcemia due to extreme local concentrations should not be a concern. However, changes such
as experimentally determined partition coefficients or more
aggressive dosing regimens could lead to larger spikes in
compartmental QD concentration. Of special interest are
maximum QD concentrations in the spleen, liver, and kidneys because these organs are richly perfused and have
been shown to accumulate QDs in mice.8,10,12 Toxic tissue
concentration of QDs could remain excessive for weeks, so
it is important to be able to predict and prevent this.
When partition coefficients are estimated with experimental tissue concentration data, any partition coefficient not
explicitly validated by the data will cause significant error in
the resulting time-concentration values. In this case, assuming the “other” compartment has a partition coefficient of 1
is a substantial source of error, as the compartment is most
of the volume in the system and receives over two-thirds of
the total blood flow. This error is easily observable due to the
large differences between the partition coefficients in Table 3
for the same organ. In this way, the partition coefficients reported are empirical and cannot be deconvoluted to find the
true physiological partition coefficient. Thus, interpretation

of a larger partition coefficient for a different QD or different
model as meaning a higher affinity for the given QD is only true
within each instance of the simulation. That is, only the relationship between partition coefficients for each compartment
in a given model can be considered. In particular, the tumor
compartment partition coefficient is quite variable and cannot
be determined with much certainty without further information.
Moreover, the experimental QD concentration measurements
used to fit the partition coefficients may contain errors whose
effects cannot be accounted for in a straightforward manner.
Not enough data exist to determine standard error at this time;
as more experimental data become available, adjustments
can be made to this framework.
For this model to be quantitatively predictive, further
experimental data are needed to estimate the partition
coefficients. The best option is conducting in vitro experiments to determine physiological partition coefficients22
so that the model could be developed fully a priori rather
than based on experimental concentration data. Currently,
the model presented is limited because the data used to
estimate the partition coefficients do not contain information about the short-time dynamics of QD distribution. The
data are for QD concentration 4 days after dosage, yet,
in this model, most dynamics happen on the time scale
of hours. This error is seen in the results, where QD concentrations peak earlier than during the second day, as
observed by Schaefer et al.10
A valuable improvement to this model is the incorporation
of the lymphatic system, which plays an important role in
IBC. In addition to blood flow, the model would include lymph
flow that comes from each compartment, goes through
a lymph node compartment, and is emptied into venous
blood. IBC tumor emboli often travel through dermal lymphatic vessels causing distant metastases.3 Symptoms are
typically observed after the initial tumor has metastasized,
so it is valuable to consider the lymphatic system as it is systematically interconnected with the network of metastases.
In addition, decoupling distribution by blood flow and lymph
flow would help explain the preference of QDs to organs that
are heavily involved in lymph flow (e.g., lungs) in tumorous
mice, even in the case of untargeted QDs.10 Furthermore,
the model could consider tumor metastasis with the addition
of a tumor subcompartment for each tissue and delumping tissues particularly susceptible to metastasis from the
“other” compartment like bone and skin. Then, tumor emboli
could be represented by concentration in blood and lymph.
More ambitiously, the presence of agents other than calcitriol that affect IBC cells, such as TGFβ, which plays a role
in IBC emboli formation as well as IBC cell clustering during
movement through the body, could supplement this tumor
metastasis model.3 Expanding the model in this way allows
for real-time quantitative simulation of IBC treatment, with
tumor growth and QD distribution occurring simultaneously.
Progress in understanding disease on the molecular level
has led to an increased popularity of personalized medicine, a
strategy where treatment depends on models that characterize
and differentiate patients based on their individual characteristics. The classic trial-and-error approach to treating disease has
many shortcomings, notably that the physician or experimentalist must make an educated guess about which treatment will
www.cts-journal.com
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be most effective, as well as when to administer it and how
much to give the patient. Allometric scaling of the compartment
volumes can be used to adapt this model for use in predicting
appropriate dosages for clinical or experimental trials with QD
IBC treatments on other animals.23 Adaptation of this model for
humans should be accompanied by specific emphasis placed
on accurate modeling of the breast compartment. Currently,
the model lacks enough experimental data to provide reliable
QD concentration estimates. However, further experimental
validation of the model would allow for dynamic quantitative
prediction of QD concentrations, which when coupled with a
well-developed therapy program could be a powerful tool for
fighting IBC. For instance, the model can be used to determine
peak concentrations as well as area under the curve (AUC) exposures, which are crucial factors in designing chemotherapy
regimens and dosing schedules. This translates to prediction
of the optimal SM3 CalQD dosage amount and frequency to
provide a target exposure of the QDs based on how developed
the IBC is, while avoiding hypercalcemia in other tissues.
This PBPK model has been constructed and validated for
multiple QDs, notably SM3 CalQDs, which are of interest for
IBC treatment. SM3 CalQDs provide a targeted calcitriol treatment for IBC cells, which is important to mitigate cancerous
effects of the tumor cells while allowing for live cell direct
imaging and avoiding hypercalcemia in patients. Further in
vitro analysis of the QDs is recommended so that currently
estimated parameters can be replaced by physiologically accurate values to complete the top-down model. This model
has potential as a predictive tool to guide or supplement both
experimental and clinical endeavors in QD treatment of IBC
with the hope that a more successful treatment is developed.
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